Treatment approaches to symptoms associated with frontotemporal degeneration.
A systematic review of the literature reveals few randomized, controlled trials for drug therapy in frontotemporal degeneration (FTD). Although there is evidence to support a serotonergic deficit, and clinicians frequently prescribe selective serotonin reuptake inhibitors to patients with FTD, only paroxetine and trazodone have been studied. There is Class II evidence for use of rivastigmine in FTD behavioral disturbances, although there is no consistent evidence of cholinergic deficit in this illness.
Chow
Tiffany W
TW
The Rotman Research Institute, 3560 Bathurst Street, 8th Floor, Posluns Building, Toronto, Ontario M6A 2E1, Canada. tchow@rotman-baycrest.on.ca
D001037:Aphasia / Q000188:drug therapy / Q000209:etiology; D017028:Caregivers / Q000523:psychology; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D003704:Dementia / Q000150:complications*; D015259:Dopamine Agents / Q000627:therapeutic use; D006801:Humans; D008559:Memantine / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D015259:Dopamine Agents; D008559:Memantine; D017367:Selective Serotonin Reuptake Inhibitors